| Literature DB >> 31034487 |
Ryuichi Kawamoto1,2, Asuka Kikuchi1,2, Taichi Akase1,2, Daisuke Ninomiya1,2, Teru Kumagi1.
Abstract
This study examined a range of anthropometric indices and their relationships with metabolic syndrome (MetS). Despite recommendations that central obesity assessment should be employed as a marker of metabolic health, there is no consensus regarding the protocol for measurement. The present study included 720 men aged 71 ± 8 years and 919 women aged 71 ± 7 years from a rural village. We examined the relationship between anthropometric indices {e.g., body mass index (BMI), waist-to-height ratio (WHtR), waist-to-hip ratio (WHpR)}, and MetS based on the modified criteria of the National Cholesterol Education Program's Adult Treatment Panel (NCEP-ATP) III report in a cross-sectional (N = 1,639) and cohort (N = 377) data. A receiver operating curve (ROC) analysis was performed to determine the optimal cut-off value and best discriminatory value of each of these anthropometric indices to predict MetS. In the cross-sectional study, WHtR as well as BMI and WHpR showed significantly predictive abilities for MetS in both genders; and WHtR showed the strongest predictive ability for the presence of MetS. Also in the cohort study, WHtR as well as BMI and WHpR showed significantly predictive abilities for incident MetS in both genders, and in men WHtR showed the strongest predictive ability for incident MetS, but in women BMI showed the strongest predictive ability. In the cross-sectional study, the optimal WHtR cutoff values were 0.52 (sensitivity, 71.0%; specificity, 77.9%) for men and 0.53 (sensitivity, 79.8%; specificity, 75.7%) for women. In the cohort study, the optimal WHtR values were 0.50 (sensitivity, 60.7%; specificity, 73.2%) for men and 0.50 (sensitivity, 75.0%; specificity, 56.1%) for women. Increased WHtR was significantly and independently associated with prevalence of MetS in both genders. These results suggest that WHtR is a useful screening tool for determining metabolic risk in Japanese elderly community dwelling individuals.Entities:
Mesh:
Year: 2019 PMID: 31034487 PMCID: PMC6488078 DOI: 10.1371/journal.pone.0216069
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart.
For the cross-sectional analyses, data of the 2014 cycle (n = 1,639) that were used in this cycle were measured. For the longitudinal analyses, only participants in whom MetS was not prevalent at baseline in 2014 were included in the longitudinal analyses (n = 377).
Baseline characteristics of study subjects.
| Baseline Characteristics N = 1,639 | Men N = 720 | Women N = 919 | |
|---|---|---|---|
| Age (years) | 71 ± 8 | 71 ± 7 | 0.602 |
| Body mass index (kg/m2) | 23.1 ± 2.9 | 22.6 ± 3.2 | |
| Waist circumference (cm) | 82.4 ± 8.1 | 80.5 ± 9.0 | |
| Waist/height ratio | 0.51 ± 0.05 | 0.54 ± 0.06 | |
| Waist/hip ratio | 0.90 ± 0.06 | 0.89 ± 0.06 | |
| Smoking habit (never/past/light/heavy (%)) | 41.7/40.6/4.3/13.5 | 96.8/2.1/0.7/0.4 | |
| Drinking Status (never/occasional/light/heavy (%)) | 24.7/22.1/16.8/36.4 | 71.6/22.1/4.6/1.7 | |
| Exercise habits (%) | 36.9 | 38.6 | 0.505 |
| Cardiovascular disease (%) | 10.3 | 4.4 | |
| Systolic blood pressure (mmHg) | 137 ± 17 | 137 ± 18 | 0.714 |
| Diastolic blood pressure (mmHg) | 80 ± 10 | 77 ± 10 | |
| Antihypertensive medication (%) | 48.1 | 45.3 | 0.272 |
| Triglycerides (mg/dl) | 90 (68–131) | 87 (65–117) | |
| HDL cholesterol (mg/dl) | 62 ± 16 | 68 ± 17 | |
| LDL cholesterol (mg/dl) | 114 ± 28 | 124 ± 29 | |
| Antidyslipidemic medication (%) | 14.0 | 30.0 | |
| Hemoglobin A 1c (%) | 5.7 (5.4–6.0) | 5.7 (5.5–5.9) | |
| Antidiabetic medication (%) | 13.6 | 5.5 | |
| Serum uric acid (mg/dL) | 6.0 ± 1.3 | 4.7 ± 1.1 | |
| Estimated GFR (ml/min/1.73 m2/year) | 69.4 ± 12.1 | 71.8 ± 10.8 | |
| Number of metabolic syndrome component | 2.3 ± 1.1 | 2.6 ± 1.2 | |
| Metabolic syndrome (%) | 37.8 | 51.1 |
HDL, high-density lipoprotein; LDL, low-density lipoprotein; GFR glomerular filtration ratio. Data presented are mean ± standard deviation. Data for triglycerides and HemoglobinA1c is skewed, and presented as median (interquartile range) values.
* P-value: Student’s t-test for the continuous variables or the χ2 -test for the categorical variables. Bold values indicate significance (p<0.05).
Fig 2Area under the receiver operating curve (AUC) values (95% CI) for selected obesity measurements to discriminate subjects with metabolic syndrome in the cross-sectional and cohort study.
Non-adjusted odds ratios and 95% CI for metabolic syndrome and its components of subjects according to baseline waist to height ratio in the cross-sectional and cohort studies.
| Cross-sectional study N = 1,639 | Men N = 720 | Women N = 919 | ||||
|---|---|---|---|---|---|---|
| Yes/No | Odds ratio (95% CI) | Yes/No | Odds ratio (95% CI) | |||
| Metabolic syndrome | 272/448 | 3.62 (2.95–4.43) | 470/449 | 3.46 (2.93–4.08) | ||
| Central obesity | 254/466 | 15.8 (10.6–23.3) | 471/448 | 19.9 (13.4–29.5) | ||
| Elevated blood pressure | 572/148 | 1.62 (1.34–1.97) | 716/203 | 1.66 (1.43–1.91) | ||
| Elevated triglycerides | 128/592 | 1.62 (1.35–1.95) | 112/807 | 1.87 (1.50–2.33) | ||
| Lowering HDL cholesterolemia | 139/581 | 1.62(1.35–1.95) | 349/570 | 1.54 (1.35–1.75) | ||
| Elevated hemoglobin A 1c | 527/193 | 1.24 (1.05–1.47) | 704/215 | 1.17 (1.02–1.34) | ||
| Metabolic syndrome | 28/149 | 1.99 (1.21–3.28) | 36/164 | 2.02 (1.34–3.06) | ||
| Central obesity | 41/136 | 5.38 (2.96–9.77) | 54/146 | 5.51 (3.29–9.23) | ||
| Elevated blood pressure | 125/52 | 1.18 (0.76–1.82) | 0.459 | 117/83 | 1.01 (0.74–1.39) | 0.956 |
| Elevated triglycerides | 21/156 | 1.03 (0.57–1.86) | 0.930 | 13/187 | 1.03 (0.55–1.93) | 0.933 |
| Lowering HDL cholesterolemia | 16/161 | 0.75 (0.36–1.57) | 0.450 | 31/169 | 1.50 (0.98–2.28) | 0.061 |
| Elevated hemoglobin A 1c | 107/70 | 0.89 (0.60–1.31) | 0.551 | 129/71 | 0.82 (0.59–1.13) | 0.219 |
CI, confidence interval.
*Bold values indicate significance (p<0.05).
Multivariate-adjusted odds ratios and 95% CI for metabolic syndrome and its components of subjects according to baseline waist to height ratio in the cross-sectional and cohort studies.
| Cross-sectional study N = 1,639 | Men N = 720 | Women N = 919 | ||||
|---|---|---|---|---|---|---|
| Yes/No | Odds ratio (95% CI) | Yes/No | Odds ratio (95% CI) | |||
| Metabolic syndrome | 272/448 | 3.82 (3.08–4.72) | 470/449 | 3.33 (2.81–3.96) | ||
| Central obesity | 254/466 | 19.5 (12.6–30.1) | 471/448 | 31.0 (19.5–49.2) | ||
| Elevated blood pressure | 572/148 | 1.57 (1.28–1.93) | 716/203 | 1.43 (1.23–1.68) | ||
| Elevated triglycerides | 128/592 | 1.59 (1.30–1.95) | 112/807 | 1.75 (1.38–2.21) | ||
| Lowering HDL cholesterolemia | 139/581 | 1.70 (1.40–2.07) | 349/570 | 1.48 (1.28–1.70) | ||
| Elevated hemoglobin A1c | 527/193 | 1.24 (1.04–1.47) | 704/215 | 1.10 (0.95–1.28) | 0.200 | |
| Metabolic syndrome | 28/149 | 1.94 (1.14–3.32) | 36/164 | 1.93 (1.23–3.03) | ||
| Central obesity | 41/136 | 5.75 (3.05–10.8) | 54/146 | 8.28 (4.28–16.0) | ||
| Elevated blood pressure | 125/52 | 1.07 (0.68–1.69) | 0.769 | 117/83 | 0.88 (0.62–1.24) | 0.467 |
| Elevated triglycerides | 21/156 | 1.07 (0.55–1.90) | 0.960 | 13/187 | 1.09 (0.55–2.19) | 0.803 |
| Lowering HDL cholesterolemia | 16/161 | 1.07 (0.48–2.37) | 0.869 | 31/169 | 1.27 (0.82–1.96) | 0.292 |
| Elevated hemoglobin A 1c | 107/70 | 0.90 (0.59–1.40) | 0.648 | 129/71 | 0.83 (0.58–1.17) | 0.280 |
*Multivariate-adjusted for age, smoking status, drinking status, exercise habits, presence of cardiovascular disease, low-density lipoprotein cholesterol, serum uric acid, and estimated GFR. Bold values indicate significance (p<0.05).
Best cutoff values of baseline waist to height ratio to predict metabolic syndrome in the cross-sectional and cohort studies.
| AUC (95% CI) | Cut off value | Sensitivity | specificity | PPV | NPV | ||
|---|---|---|---|---|---|---|---|
| Men N = 720 | 0.812 (0.780–0.844) | 0.5185 | 71.0% | 77.9% | 76.3% | 72.9% | |
| Women N = 919 | 0.832 (0.806–0.859) | 0.5349 | 79.8% | 75.7% | 76.7% | 78.9% | |
| Men N = 177 | 0.698 (0.600–0.797) | 0.4991 | 60.7% | 73.2% | 69.4% | 63.1% | |
| Women N = 200 | 0.681 (0.591–0.772) | 0.4957 | 75.0% | 56.1% | 62.2% | 69.2% |
AUR, Area under the receiver operating curve; PPV: positive predictive value; NPV: negative predictive value. Bold values indicate significance (p<0.05).